Therapeutics and COVID-19: living guideline

Published by World Health Organization on Jan 13, 2022

Disclaimer

WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.

 

© World Health Organization 2022. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.

WHO reference number: WHO/2019-nCoV/therapeutics/2022.1

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Patients with severe or critical COVID-19
Intervention
Baricitinib
Comparator
Standard care
Outcomes

PICO 1.2

Population
Patients with severe and critical COVID-19
Intervention
Baricitinib
Comparator
Interleukin-6 receptor blockers
Outcomes

PICO 1.3

Population
Patients with severe or critical COVID-19
Intervention
Ruxolitinib
Comparator
Standard care
Outcomes

PICO 1.4

Population
Patients with severe or critical COVID-19
Intervention
Tofacitinib
Comparator
Standard care
Outcomes

PICO 2.1

Population
Patients with non-severe COVID-19
Intervention
Sotrovimab
Comparator
Standard care
Outcomes

PICO 2.2

Population
Patients with non-severe COVID-19
Intervention
Sotrovimab
Comparator
Casirivimab-imdevimab
Outcomes

PICO 3.1

Population
Patients with non-severe COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 3.2

Population
Patients with severe or critical COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 4.1

Population
Patients with non-severe COVID-19
Intervention
Casirivimab-imdevimab
Comparator
Standard care
Outcomes

PICO 4.2

Population
Patients with severe or critical COVID-19, seronegative
Intervention
Casirivimab-imdevimab
Comparator
Standard care
Outcomes

PICO 4.3

Population
Patients with severe or critical COVID-19
Intervention
Casirivimab-imdevimab
Comparator
Standard care
Outcomes

PICO 4.4

Population
BY RISK (not used) - Patients with non-severe COVID-19
Intervention
Casirivimab and imdevimab
Comparator
No casirivimab and imdevimab
Outcomes

PICO 4.5

Population
Patients with COVID-19 (all severities)
Intervention
Casirivimab and imdevimab
Comparator
No casirivimab and imdevimab
Outcomes

PICO 5.1

Population
Patients with severe or critical COVID-19
Intervention
Interleukin-6 receptor blockers
Comparator
Standard care
Outcomes

PICO 5.2

Population
MOCK-UP Stratified baseline risk_Patients withCOVID-19 infection (all disease severities)
Intervention
IL-6 inhibitor
Comparator
Standard care
Outcomes

PICO 5.3

Population
Patients with COVID-19 (all disease severities)
Intervention
Tocilizumab + steroids
Comparator
Sarilumab + steroids
Outcomes

PICO 6.1

Population
Patients with non-severe COVID-19
Intervention
Colchicine
Comparator
No colchicine
Outcomes

PICO 6.1

Population
Patients with COVID-19 (all disease severities)
Intervention
Ivermectin
Comparator
Standard care
Outcomes

PICO 6.2

Population
Patients with non-severe COVID-19 (Tardif only)
Intervention
Colchicine
Comparator
No colchicine
Outcomes

PICO 6.3

Population
Patients with severe COVID-19
Intervention
Colchicine
Comparator
No colchicine
Outcomes

PICO 6.4

Population
Patients with severe or critical COVID-19
Intervention
Janus kinase inhibitors
Comparator
No Janus kinase inhibitor
Outcomes

PICO 6.5

Population
Patients with severe or critical COVID-19
Intervention
Janus kinase inhibitors
Comparator
Interleukin-6 receptor blockers with glucocorticoids
Outcomes

PICO 6.6

Population
Patients with non-severe COVID-19
Intervention
Convalescent plasma
Comparator
No convalescent plasma
Outcomes

PICO 6.7

Population
Patients with severe and critical COVID-19
Intervention
Ruxolitinib
Comparator
Interleukin 6-receptor blockers
Outcomes

PICO 6.8

Population
Patients with severe and critical COVID-19
Intervention
Tofacitinib
Comparator
Interleukin 6-receptor blockers
Outcomes

PICO 6.9

Population
Patients with non-severe COVID-19
Intervention
Molnupiravir
Comparator
No molnupiravir
Outcomes

PICO 6.10

Population
Patients with non-severe COVID-19
Intervention
Fluvoxamine
Comparator
No fluvoxamine
Outcomes

PICO 6.11

Population
Patients with non-severe COVID-19
Intervention
Nirmatrelvir/ritonavir
Comparator
No nirmatrelvir/ritonavir
Outcomes

PICO 7.1

Population
Patients with COVID-19 (all disease severities)
Intervention
Hydroxychloroquine
Comparator
Standard care
Outcomes

PICO 7.2

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Hydroxychloroquine + azithromycin usual care
Comparator
Usual care
Outcomes

PICO 7.3

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Hydroxychloroquine + usual care
Comparator
Usual care
Outcomes

PICO 8.1

Population
Patients with COVID-19 (all disease severities)
Intervention
Lopinavir/ritonavir
Comparator
Standard care
Outcomes

PICO 9.1

Population
Patients with COVID-19 (all disease severities)
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 9.2

Population
Patients with critical COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 9.3

Population
Patients with severe COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 9.4

Population
Patients with non-severe COVID-19 infection
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 9.5

Population
Patients with COVID-19 infection (mortality subgroup analysis)
Intervention
Remdesivir + usual care
Comparator
Usual care
Outcomes

PICO 10.1

Population
Patients with severe or critical COVID-19 (updated baseline mortality risk)
Intervention
Systemic corticosteroids
Comparator
Standard care
Outcomes

PICO 10.2

Population
Patients with non-severe COVID-19
Intervention
Systemic corticosteroids
Comparator
Standard care
Outcomes

PICO 10.3

Population
Patients with severe COVID-19
Intervention
Steroids
Comparator
Standard care
Outcomes

PICO 10.4

Population
Patients with critical COVID-19
Intervention
Steroids
Comparator
Standard care
Outcomes

PICO 10.5

Population
Patients with COVID-19 infection (all disease severities)
Intervention
Steroids
Comparator
Standard care
Outcomes

PICO 10.6

Population
Patients with critical, severe, non-severe COVID-19 infection [Mortality]
Intervention
Steroids
Comparator
Standard care
Outcomes